Combination therapy of dexamethasone, rituximab, and cyclosporine for adults with primary immune thrombocytopenia: a prospective observational study
The combination of dexamethasone, rituximab, and cyclosporine may present a promising therapeutic option for patients with refractory ITP, with good tolerability and mild adverse reactions.
Authors
- Yi Fang (ORCID: https://orcid.org/0000-0002-3547-5829)
- Anqi Zhao (ORCID: https://orcid.org/0000-0001-6006-9796)
- Cong Tang (ORCID: https://orcid.org/0000-0003-1661-6793)
- Ying Liang (ORCID: https://orcid.org/0000-0001-9092-2110)
- Chunyu Liu (ORCID: https://orcid.org/0000-0002-5986-4415)
- Lu Zhang (ORCID: https://orcid.org/0000-0002-0860-9625)
- Nannan Chen (ORCID: https://orcid.org/0000-0002-0152-1444)
Institutions
- People's Liberation Army 401 Hospital (CN)
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1080/17474086.2024.2420633
- Citations
- 2
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Natural Science Foundation of Liaoning Province